Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00447
|
|||||
| Drug Name |
Nevirapine
|
|||||
| Synonyms |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; BI RG 587; BI-RG-587; BI-RG-587 & CD4-IgG; BIRG 0587; BIRG 587; BIRG-0587; BIRG-587; BIRG587; Cahill May Roberts Brand of Nevirapine; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; NEV; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; NVP; Nevirapine & CD4-IgG; Nevirapine & PRO 140; Nevirapine (JAN/USP/INN); Nevirapine [USAN:INN]; Promeco Brand of Nevirapine; Viramune; Viramune (TN); Viramune(TM); Viramune, BI-RG 587, Nevirapine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11:1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H14N4O
|
|||||
| Canonical SMILES |
CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
|
|||||
| InChI |
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
|
|||||
| InChIKey |
NQDJXKOVJZTUJA-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 129618-40-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 266.3 | Topological Polar Surface Area | 58.1 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
12014582
,14716699
,14716702
,14872507
,17388862
,24721613
,26718578
,26719643
,29223558
,46386569
,46393424
,46394249
,46506789
,48425381
,49718173
,49856363
,500792
,50086444
,50622552
,53789571
,5596797
,56313692
,56313770
,57322283
,597607
,601303
,7847501
,7889356
,7889505
,7980115
,8031304
,81093307
,8152750
,819817
,823573
,823576
,826050
,826057
,826059
,826060
,832211
,832214
,833983
,85173516
,865943
,866527
,92308419
,92712790
,93166484
,9472
|
|||||
| ChEBI ID |
ChEBI:63613
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Nevirapine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.